Patients are at the center of Bristol-Myers Squibb’s mission of discovering, developing and delivering innovative medicines in areas of significant unmet medical need. In many cases, our medicines are being studied as potential treatments for patients with limited to no viable treatment options. It is exactly with these patients in mind that we work to make our medicines available to as many patients as possible through the conduct of well-controlled clinical trials and the successful registration of our medicines with health authorities.
Recognizing the challenges of patients who may have limited treatment options, in certain cases Bristol-Myers Squibb may offer investigational medicines in late stage development to patients outside of clinical trials. We consider these requests individually, evaluating the degree of unmet medical need and the extent of available safety and efficacy data on the compound, with patient safety as the priority. Our full policy on expanded access programs can be viewed here.